Winship Cancer Institute of Emory University | Strategic Alliance Partners

July 30, 2024

Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.

July 23, 2024

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

July 23, 2024

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

July 12, 2024

As the lung cancer paradigm continues to advance, increasingly effective therapies are under development for previously underserved disease subtypes.

July 11, 2024

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

July 02, 2024

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

June 29, 2024

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

June 27, 2024

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

June 14, 2024

Kevin Kalinsky, MD, MS, discusses the utility of the postMONARCH trial regimen in hormone receptor–positive/HER2-negative advanced breast cancer.

June 09, 2024

Anthony Hunter, MD, discusses JAK inhibitor selection in myelofibrosis in the first line and beyond.

June 02, 2024

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.

June 02, 2024

Abemaciclib plus fulvestrant improved PFS vs fulvestrant alone in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

May 29, 2024

Vikram M. Narayan, MD, discusses the utility of nadofaragene firadenovec in patients with non–muscle-invasive bladder cancer and beyond.

May 17, 2024

Vikram M. Narayan, MD, discusses the final 5-year analysis of a phase 3 trial of nadofaragene firadenovec in patients with BCG-unresponsive NMIBC.

May 15, 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

May 15, 2024

As investigators parse out the mechanism of action of nadofaragene firadenovec, additional gene therapies are under development in BCG-unresponsive NMIBC.

May 13, 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

May 10, 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

May 05, 2024

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

April 23, 2024

Vikram Narayan, MD, discusses the mechanism of action of nadofaragene firadenovec in patients with high-risk non–muscle invasive bladder cancer.